Prostatis Group’s American Express AXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$255K Sell
842
-40
-5% -$13.4K 0.07% 155
2025
Q4
$326K Sell
882
-402
-31% -$144K 0.08% 130
2025
Q3
$427K Sell
1,284
-41
-3% -$13K 0.11% 103
2025
Q2
$423K Sell
1,325
-662
-33% -$186K 0.12% 103
2025
Q1
$535K Sell
1,987
-3
-0.2% -$887 0.17% 92
2024
Q4
$591K Sell
1,990
-3,852
-66% -$1.11M 0.17% 94
2024
Q3
$1.58M Buy
5,842
+1,095
+23% +$273K 0.52% 47
2024
Q2
$1.12M Buy
4,747
+67
+1% +$15.5K 0.39% 59
2024
Q1
$1.06M Buy
4,680
+1,361
+41% +$282K 0.4% 58
2023
Q4
$622K Buy
3,319
+88
+3% +$14.2K 0.26% 76
2023
Q3
$474K Buy
+3,231
New +$528K 0.23% 68

Other funds holding AXP

Prostatis Group's AXP Position: Q1 2026 in Review

Prostatis Group reduced its American Express (AXP) stake by 4.5% in Q1 2026, selling an estimated $13.4K and leaving 842 shares worth $255K. The position accounts for 0.07% of the portfolio, ranked #155.

Prostatis Group first reported a position in AXP in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.58M in Q3 2024. 2,888 funds tracked by Wall St. Rank hold AXP as of Q1 2026.

  • Prostatis Group held 842 shares of American Express worth $255K as of Q1 2026.
  • Prostatis Group sold 40 American Express shares in Q1 2026, an estimated $13.4K.
  • American Express made up 0.07% of Prostatis Group's portfolio in Q1 2026, its #155 holding.
  • Prostatis Group first reported a position in American Express in Q3 2023 and has held it in 11 quarters since.
  • Prostatis Group's American Express position peaked at $1.58M in Q3 2024.
  • 2,888 funds tracked by Wall St. Rank held American Express as of Q1 2026.

Based on Prostatis Group's 13F filing for Q1 2026, filed 12 May 2026.